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OPEN
ARTICLE
IHC-based subcellular quantiﬁcation provides new insights
into prognostic relevance of FLIP and procaspase-8 in
non-small-cell lung cancer
Ryan A Hutchinson1, Helen G Coleman2, Kathy Gately3, Vincent Young3, Siobhan Nicholson3, Robert Cummins4, Elaine Kay4,
Sean O Hynes1, Philip D Dunne1, Seedevi Senevirathne1, Peter W Hamilton1, Darragh G McArt1,5 and Daniel B Longley1,5
In this study, we developed an image analysis algorithm for quantiﬁcation of two potential apoptotic biomarkers in non-small-cell
lung cancer (NSCLC): FLIP and procaspase-8. Immunohistochemical expression of FLIP and procaspase-8 in 184 NSCLC tumors were
assessed. Individual patient cores were segmented and classiﬁed as tumor and stroma using the Deﬁniens Tissue Studio.
Subsequently, chromogenic expression of each biomarker was measured separately in the nucleus and cytoplasm and reported as
a quantitative histological score. The software package pROC was applied to deﬁne biomarker thresholds. Cox proportional hazards
analysis was applied to generate hazard ratios (HRs) and associated 95% CI for survival. High cytoplasmic expression of tumoral (but
not stromal) FLIP was associated with a 2.5-fold increased risk of death in lung adenocarcinoma patients, even when adjusted for
known confounders (HR 2.47, 95% CI 1.14–5.35). Neither nuclear nor cytoplasmic tumoral procaspase-8 expression was associated
with overall survival in lung adenocarcinoma patients; however, there was a signiﬁcant trend (P for trend= 0.03) for patients with
adenocarcinomas with both high cytoplasmic FLIP and high cytoplasmic procaspase-8 to have a multiplicative increased risk of
death. Notably, high stromal nuclear procaspase-8 expression was associated with a reduced risk of death in lung adenocarcinoma
patients (adjusted HR 0.31, 95% CI 0.15–0.66). On further examination, the cells with high nuclear procaspase-8 were found to be of
lymphoid origin, suggesting that the better prognosis of patients with tumors with high stromal nuclear procaspase-8 is related to
immune inﬁltration, a known favorable prognostic factor. No signiﬁcant associations were detected in analysis of lung squamous
cell carcinoma patients. Our results suggest that cytoplasmic expression of FLIP in the tumor and nuclear expression of procaspase-
8 in the stroma are prognostically relevant in non-small-cell adenocarcinomas but not in squamous cell carcinomas of the lung.
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INTRODUCTION
Non-small-cell lung cancer (NSCLC) accounts for approximately 85%
of all lung cancer diagnoses and is the most common cause of death
from cancer globally.1–3 The AJCC/UICC-TNM system remains the
gold standard for assessing patient prognosis; however, it gives no
prediction for treatment beneﬁt. NSCLC has one of the lowest 5-year
survival rates of all cancers; therefore, the discovery of new
biomarkers that can be used as predictive, prognostic, therapeutic
or diagnostic tools is of increasing importance. Over the years,
numerous molecular pathways and processes have been identiﬁed
that underpin lung cancer pathogenesis.4–9 One of the most
investigated mechanisms in cancer research has been apoptosis,
which frequently becomes dysregulated and contributes signiﬁ-
cantly to both disease progression and drug resistance.10,11
Apoptosis is an essential physiological mechanism that regulates
cell proliferation and tissue homeostasis, which is why its
dysregulation is one of the hallmarks of cancer.
Fas-associated death domain-like interleukin 1β-converting
enzyme (FLICE)-inhibitory protein (FLIP) is a major apoptosis
inhibitor, and its overexpression inhibits the activation of caspase-
8 (FLICE)-mediated apoptosis.12 Clinical analyses have revealed
that FLIP is frequently overexpressed in many cancers, including
NSCLC.12 In addition, previous studies have shown that FLIP
expression correlates with tumoral metastatic potential, which
may be related to its ability to inhibit anoikis, a form of cell death
induced following detachment of anchorage-dependent cells
from their extracellular matrix.13,14 Procaspase-8 is an initiator
caspase that has been found to be inactivated through epigenetic
or genetic mechanisms in a subset of human cancers, such as
small-cell lung cancer (SCLC); however, the majority of solid
tumors appear to retain procaspase-8 expression or even have
elevated procaspase-8 expression compared with adjacent normal
tissues.15 Although the reasons for this are unclear, retention or
elevation of procaspase-8 levels may be selected for during
tumorigenesis or therapeutic intervention, because in complex
with the long FLIP splice form (FLIPL), procaspase-8 suppresses
another form of cell death termed programmed necrosis or
‘necroptosis’.16,17 Thus a delicate interplay exists between FLIP and
procaspase-8 that is critical for regulating at least two major forms
of cell death and that can therefore have a major impact on
disease progression and response to a range of anticancer
therapeutics. For example, we have previously demonstrated in
several cancers including NSCLC that downregulating FLIP
enhances chemotherapy-induced apoptosis in a caspase-8
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dependent manner, whereas overexpression of FLIP blocks
caspase-8-mediated apoptosis.15,18,19
NSCLC consists of several histological subtypes, of which
adenocarcinoma and squamous cell carcinoma predominate.20
In this study, we used a digital pathology approach for measuring
FLIP and procaspase-8 expression in the cytoplasmic and nuclear
compartments of NSCLC tissues. Because of the increasingly
recognized importance of the tumor microenvironment, we also
determined the expression of both proteins in the adjacent
stromal regions. Our ﬁndings indicate that high cytoplasmic FLIP
expression in tumor cells is an important determinant of patient
prognosis for non-small-cell adenocarcinoma but not for squa-
mous carcinoma. Moreover, we unexpectedly found that high
nuclear expression of procaspase-8 in the stromal compartment is
strongly associated with improved prognosis.
RESULTS
Automated quantiﬁcation of FLIP and procaspase-8
A tissue microarray (TMA) was constructed using normal and
tumor tissues from a cohort of 184 NSCLC patients and
immunohistochemically assessed for the expression of FLIP and
procaspase-8.21 To achieve both automated quantiﬁcation and
obtain a continuous range of FLIP and procaspase-8 staining
intensities, the TMA images were imported into Deﬁniens Tissue
Studio (Deﬁniens AG, Munich, Germany), an image analysis
software platform that supports the design, development and
application of new image analysis algorithms. For each of the
biomarkers being investigated in this study, a novel image analysis
method was created using the following steps:
(1) Automated tumor identiﬁcation. Once imported into Deﬁ-
niens, a custom grid was deﬁned to match the layout of the TMA.
Patient clinical metadata were linked to each core, and the cores
were then digitally ‘de-arrayed’ to generate individual cores and
assign array coordinates to match the layout of the original TMA
(Figure 1a). Twelve of the de-arrayed cores, which demonstrated a
range of biomarker expression positivity, were used in a training
set (Figure 1a). First, a threshold to distinguish between back-
ground and whitespace was deﬁned using a combination of
thresholds, which included a homogeneity threshold that
segmented the image into homogeneous and non-
homogeneous regions. These segmented regions were then
classiﬁed as background and tissue core; additionally, a minimum
area parameter that classiﬁed artifacts as part of the background
was included. Each individual tissue core was segmented into
super-pixels using a multi-resolution segmentation algorithm
(Figure 1b), which partitioned the image into spectrally coherent
regions. Within each super-pixel, the brown chromogen intensity,
hematoxylin intensity, area and shape as well as customized
arithmetic (ratios of hematoxylin to brown chromogen intensity)
and temporo-spatial features (distance of tumor regions to stroma
and whitespace) were measured. Using these features, in
combination with a machine learning approach, each super-
pixel was classiﬁed as either tumor or stroma (Figure 1c). From
each of these classiﬁed super-pixels, nuclei, cytoplasm and cell
boundaries were identiﬁed (Figure 1d). This subsequently allowed
the separate quantitative analysis of protein expression in both
the tumor and stromal compartments. Before the algorithm was
applied across the complete patient cohort, an experienced
Pathologist conﬁrmed that the identiﬁcation and classiﬁcation of
regions was accurate in an independent training set.
(2) Detection and classiﬁcation of tumoral and stromal nuclei. A
stain deconvolution algorithm was used to separate the DAB
chromogen stain and the hematoxylin counterstain in all tissue
cores. Using super-pixels to deﬁne tissue compartments,
thresholds were identiﬁed to distinguish between positive and
negative nuclear expression of each protein using the image
object information table within the software. Nuclei were
segmented on a nucleus-by-nucleus basis, which enabled
visualization of multi-parametric features of each individual
nucleus (Figure 1d). The image object table enables the identiﬁed
nuclei to be sorted by features of interest; in this case,
morphology, hematoxylin intensity and brown chromogen
intensity were used. From these features, brown chromogen
intensity and hematoxylin intensity thresholds were determined,
and we used these to segment and identify both positive and
negative nuclei within the tumor and positive and negative nuclei
within stromal regions. Using this information, a nuclei ﬁlter was
applied, which enabled us to remove nuclei that did not match
the morphological and staining criteria. Nuclei were identiﬁed
based on measures of their size, sphericity, optical density and
level of overlap. A nucleus classiﬁcation module was added to the
algorithm, and using the image object information table, the
minimum and maximum brown chromogen intensity of each
individual positive nucleus was determined. Nuclei detected using
the hematoxylin threshold remained negative when the chromo-
genically positive nuclei were classiﬁed.
(3) Identiﬁcation of cell boundaries and cytoplasmic compartments.
In order to be able to assess the cytoplasmic intensity of the
proteins, cell simulation was used to ‘grow’ a cytoplasmic
compartment for each cell from the detected nucleus. Using the
training set, a ‘region of growth’ of 4 μm was identiﬁed as the
optimal threshold for cell border generation; the growth and
morphology of these generated cells were determined through
the visualization of a ‘cell mask’. From this cell simulation module,
the area between the identiﬁed nucleus and cell boundary was
classiﬁed as cytoplasm. The ﬁnal stage in the algorithm develop-
ment was to classify cytoplasmic expression of each biomarker
within the regions of interest. The brown chromogen intensity of
each individual cytoplasmic region was used to determine the
threshold for cytoplasmic expression of each biomarker.
(4) Determination of a compartment-speciﬁc biomarker histological
score (H-score). From the segmented and classiﬁed tumoral and
stromal cells, the expression was quantiﬁed in each compartment,
and using brown chromogen intensity and hematoxylin intensity
thresholds, a H-score was calculated for nuclear and cytoplasmic
FLIP and procaspase-8 using the formula: (1 ×percentage of low
brown chromogen intensity-positive cells)+(2×percentage of med-
ium brown chromogen intensity-positive cells)+(3×percentage of
high brown chromogen intensity-positive cells) based on the
quantitative data generated from the image analysis algorithm.
Utilizing Deﬁniens Image Miner 2.0 (Deﬁniens AG, Munich,
Germany), we created a customized data repository, which linked
the clinicopathological data with the quantitative image analysis
data. When the algorithm was applied across each TMA, a quality
control step was adopted to ensure the algorithm was performing
robustly and was not speciﬁc to the training set. Random cores were
selected from each analyzed TMA, and the tumor identiﬁcation
method, cellular segmentation and quantiﬁcation were checked by
two of the study investigators (RAH and PWH).
High cytoplasmic FLIP in tumor cells is an adverse prognostic
marker in adenocarcinoma
Table 2 shows the association between overall survival of lung
adenocarcinoma patients and the expression of tumoral and
stromal FLIP and procaspase-8 expression within the nucleus and
cytoplasm. High cytoplasmic expression of tumoral FLIP (H-score
4172.5) was associated with a two-fold increased risk of death in
lung adenocarcinoma patients, which strengthened further when
adjusted for known confounders (HR 2.47, 95% CI 1.14–5.35;
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Table 2; Figure 2a). High tumoral FLIP nuclear expression
(H-score4105) was also associated with an increased risk of
death, although this did not achieve statistical signiﬁcance. In
contrast, higher stromal FLIP expression in the nucleus and
cytoplasm was associated with non-signiﬁcant decreased risks
of death.
High nuclear caspase-8 in stroma is a favorable prognostic marker
in adenocarcinoma
Neither nuclear nor cytoplasmic tumoral procaspase-8 expression
was associated with overall survival in lung adenocarcinoma
patients. Unexpectedly, however, high stromal nuclear procaspase-
8 expression (H-score490.5) was associated with a reduced risk of
death in lung adenocarcinoma patients, which was signiﬁcant when
considering nuclear expression (adjusted HR 0.31, 95% CI 0.15–0.66;
Table 2, Figure 2b). Results remained largely similar in sensitivity
analysis excluding patients who died in the ﬁrst 6 months of
follow-up (data not shown). There was also a similar trend with
high stromal cytoplasmic procaspase-8 expression (H-score4139.5),
although this did not reach signiﬁcance (adjusted HR 0.51,
95% CI 0.23–1.11). Under further pathological examination
(RAH, SH, PWH), the stromal cells expressing high procaspase-8
had clear lymphoid cell characteristics, suggesting that high stromal
procaspase-8 expression identiﬁes tumors with high degree of
immune inﬁltration.
Notably, no signiﬁcant associations between overall survival of
lung squamous cell carcinoma patients and expression levels of
either protein in the nucleus or cytoplasm of tumor or stroma
were observed (Table 3), suggesting that FLIP and procaspase-8
are more relevant in non-small-cell lung adenocarcinomas.
Figure 1. (a) Each patient’s core was individually de-arrayed from the digital slide, and patient metadata was assigned to each core for future
data mining and clinical correlations. (b) To develop an automated tumor stroma classiﬁer, each core was segmented into super-pixels using a
multi-resolution segmentation algorithm. (c) Subpanel (i) shows an individual patient core, which in subpanel (ii) was subjected to a stain
isolation algorithm that was used to separate the image into positive and negative staining. In subpanel (iii), super-pixels were classiﬁed as
either tumor (orange) or stroma (sky blue); regions of necrosis (deep blue) were also identiﬁed. (d) Following tumor and stroma assignment in
subpanel (i), regions were resegmented and a generic nucleus detection algorithm was applied, shown in subpanel (ii) with nuclei of various
morphologies coloured yellow. Subsequently, as depicted in subpanel (iii), classiﬁcation of tumor nuclei (blue) within the tumor matrix (green)
and stromal nuclei (pink) within the stromal matrix (yellow) was performed.
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FLIP/procaspase-8 correlation and combined prognostic relevance
Given that FLIP is a key modulator of procaspase-8 activation in
the cytoplasm and that these proteins are transcribed from the
same genetic locus (2q33-q34), we examined whether there was a
correlation between their expression at the protein level. In the
overall patient cohort, there was no signiﬁcant correlation
between expression of the two proteins; however, in the
squamous (but not the adenocarcinoma) subset, a signiﬁcant
positive correlation was observed (r= 0.25, P= 0.02; Figure 3a). We
further determined whether combined assessment of cytoplasmic
FLIP and caspase-8 expression had prognostic relevance.
Although, no signiﬁcant associations between individual com-
bined categories and death were observed, there was a signiﬁcant
trend (P for trend = 0.03) for patients with adenocarcinomas with
Figure 2. Kaplan–Meier graphs showing overall survival in lung adenocarcinoma patients according to: (a) tumor cytoplasmic FLIP expression;
and (b) stromal nuclear procaspase-8 expression. CI, conﬁdence interval; HR, hazard ratio.
Figure 3. (a) Scatterplot showing correlations between tumor cytoplasm expression of FLIP and procaspase-8. Pearson’s correlation
coefﬁcients were generated in the adenocarcinoma and squamous cell carcinoma subtypes separately and in the entire study cohort.
(b) Unadjusted hazard ratios (HRs) and 95% conﬁdence intervals (CIs) for risk of death in lung adenocarcinoma and squamous cell carcinoma
patients according to combined categories of high and low FLIP and procaspase-8 cytoplasm expression levels. Cutoffs for high and low
expression are outlined in Tables 2 and 3.
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both high cytoplasmic FLIP and high cytoplasmic procaspase-8
having a multiplicative increased risk of death; however, no such
association was observed in the squamous histology subgroup
(Figure 3b).
DISCUSSION
Procaspase-8 and its endogenous inhibitor FLIP are key regulators
of the extrinsic apoptotic pathway activated by cell surface death
receptors and are also key regulators of cell death induced by
cytoplasmic complexes, such as the ripoptosome.12,22 We have
previously reported that FLIP and procaspase-8 expression are key
determinants of response to chemotherapy and ionizing radiation
in preclinical models of NSCLC.15,23 We therefore used a digital
pathology approach to evaluate nuclear and cytoplasmic FLIP and
procaspase-8 expression in a cohort of NSCLCs containing both
adenocarcinoma and squamous cell carcinoma histological
subtypes.
By deﬁning H-score cutoffs using the ROC approach and by
performing multivariate analyses that demonstrate that cytoplas-
mic FLIP expression is an independent prognostic factor in
adenocarcinoma patients but not in squamous cell carcinoma
patients, this study reﬁnes our previous ﬁndings that high
cytoplasmic FLIP expression is a biomarker of poor prognosis in
NSCLC.21 Of note, nuclear FLIP expression was not signiﬁcantly
prognostic in adenocarcinoma patients, highlighting the value of
analyzing protein expression at a subcellular level. Our previous
analysis of this patient cohort using a generic method for scoring
procaspase-8 failed to identify the prognostic signiﬁcance of
nuclear procaspase-8 in the stromal compartment that was
revealed in this study, further underlining the potential utility of
this methodological approach.
As a major inhibitor of cell death induced by death ligands
expressed by immune effector cells, high FLIP expression has been
shown to promote immune escape of tumors in mouse models.24
Hence, it is plausible that FLIP overexpression is selected for
during tumorigenesis to enable tumor cells evade immune
elimination via apoptosis. Also, as noted above, FLIP confers
resistance to chemotherapy- and ionizing radiation-induced
apoptosis,15,23 which is again consistent with the association that
we have observed between high FLIP expression and poor
prognosis. Unlike SCLCs, which frequently lose procaspase-8
expression,25 NSCLCs tend to maintain or even overexpress
procaspase-8.15 This may be driven by the necessity to suppress
another form of cell death, necroptosis; procaspase-8 and FLIPL
form an enzymatic complex, which although lacking the ability to
promote apoptosis, can cleave receptor-interacting kinase-1, a key
mediator of necroptosis.22
We have previously demonstrated that depletion of FLIP using
histone deacetylase (HDAC) inhibitors, such as Entinostat, which
has recently been FDA approved for the treatment of aromatase
inhibitor-resistant, estrogen receptor-positive breast cancer,
results in caspase-8-dependent apoptosis induction and enhances
the antitumor effects of chemotherapeutic agents, ionizing
radiation and TRAIL.15,21,23 The results presented here suggest
that HDAC inhibitors or other agents that target FLIP could
potentially be targeted against poor prognostic lung adenocarci-
nomas expressing high cytoplasmic levels of FLIP. Similarly,
tumors with low cytoplasmic FLIP expression may be effectively
targeted with TRAIL receptor-targeted therapeutics, the second
generation of which are in preclinical and clinical
development.26,27 Another emerging targeted therapy are the
IAP antagonists (also referred to as SMAC mimetics),28 which we
have shown are dependent on FLIP for their efﬁcacy;29 thus these
agents may also be most effective in NSCLCs with low cytoplasmic
FLIP expression.
Given their close biological relationship, we assessed the
correlation between FLIP and procaspase-8 protein expression
and their combined prognostic relevance. Although cytoplasmic
expression of FLIP and procaspase-8 were more strongly
correlated in squamous cell carcinomas, the combined expression
of these proteins was more prognostic in adenocarcinoma. Of
note, high nuclear procaspase-8 expression was apparent in cells
of lymphoid morphology in the stroma of tumors of adenocarci-
noma patients with good prognosis. Although predominantly
expressed in the cytoplasm, sumoylated caspase-8 translocates to
the nucleus.30 Moreover, caspase-8 has been reported to have a
broad role in the activation of immune cells; for example, caspase-
8 has been shown to be essential for T-cell proliferation, as speciﬁc
deletion of the gene encoding caspase-8 (CASP8) in T cells results
in depletion of the peripheral T-cell population, thereby impairing
immune responses.12,31–33 It is possible that lymphoid cells with
high nuclear caspase-8 promote antitumor immunity, which could
explain the association between high nuclear procaspase-8 in the
stromal compartment and good prognosis. Indeed, high density of
CD4 and CD8 positive T cells in cancer stroma has been correlated
with longer survival times in NSCLC patients.34,35
In conclusion, this study demonstrates the potential of digital
imaging to quantify immunohistochemical expression of putative
biomarkers in tumor and stromal compartments at a subcellular
level to generate a quantiﬁed output, in this case a region-speciﬁc
H-score. The methodology described herein could ultimately be
developed to stratify adenocarcinoma NSCLC patients for
therapies that are dependent on FLIP and procaspase-8 expres-
sion for their activity.
Table 1. Characteristics of lung cancer patients according to
histological subtype
Characteristic Adenocarcinoma,
n=86
Squamous cell
carcinoma, n= 89
Age, years, median
(range)
65.7 (42.5–82.7) 66.0 (41.4–86.2)
Sex, n (%)
Male 46 (53.5) 63 (70.8)
Female 40 (46.5) 26 (29.2)
Tumor stage, n (%)
I 49 (57.0) 46 (51.7)
II 14 (16.3) 26 (29.2)
III 23 (26.7) 17 (19.1)
Tumor grade, n (%)
I 9 (10.5) 2 (2.2)
II 51 (59.3) 55 (61.8)
III 26 (30.2) 32 (36.0)
Tumor size, cm, median
(range)
3.8 (1–14) 4.0 (0.9–16)
Smoking status
Current 26 (30.2) 26 (29.2)
Former 53 (61.6) 60 (67.4)
Never 7 (8.1) 3 (3.4)
Surgery type, n (%)
Lobectomy 69 (80.2) 60 (67.4)
Bilobectomy 10 (11.6) 4 (4.5)
Pneumonectomy 7 (8.1) 25 (28.1)
Vital status by end of follow-up, n (%)
Alive 35 (40.7) 37 (41.6)
Dead 51 (59.3) 52 (58.4)
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SUBJECTS AND METHODS
Clinicopathological details
The tissue samples used in this study are from a cohort of 184 NSCLC
patients (86 adenocarcinomas, 9 other histologies and 89 squamous cell
carcinomas) of various stages from St James’ Hospital, Dublin, Ireland. As
shown in Table 1, 59 and 58% of lung adenocarcinoma and squamous cell
carcinoma patients had died by the end of the follow-up period (median
3.8 years, range 0.01–7.4 years), respectively. Nine lung adenocarcinoma
and 13 squamous cell carcinoma patients died within the ﬁrst 6 months,
and 16 patients of each histological subtype died within the ﬁrst year of
follow-up. The median age at surgery for lung cancer patients was 66
years. Slightly more males than females were included, particularly in the
squamous cell carcinoma group (70.8 versus 29.2%). The majority of lung
cancer patients were current or former smokers. The majority of tumors
represented early pathological stage (52–57% Stage I), tumor grade II
(59–62%) and a median tumor size of approximately 4 cm in both
histological subgroups. Most lung adenocarcinoma patients underwent
lobectomy (80.2%), with the remainder requiring more extensive surgical
resection. The majority of lung squamous cell carcinoma patients also
underwent lobectomy (67.4%); however, a greater proportion of this
patient group required pneumonectomy compared with adenocarcinoma
patients (28.1 versus 8.1%).
Immunohistochemical detection methods
Anti-caspase-8 (11B6, Leica Microsystems, Milton Keynes, UK) and anti-FLIP
(G-11, Santa Cruz, Heidelberg, Germany) antibodies were used as
previously described, with hematoxylin used as a counterstain.36
Digital image acquisition
The TMAs were comprised of three tumor cores and three cores of
adjacent normal stroma for each patient. Following immunohistochemical
staining, each TMA was digitally scanned at high resolution in the Digital
Pathology Laboratory, Northern Ireland Molecular Pathology Laboratory
within the Centre for Cancer Research and Cell Biology, Queen’s University,
Belfast, UK. The slides were scanned using an Aperio ScanScope CS (Aperio
Technologies, San Diego, CA, USA) at a resolution of 40× using the
objective 40× /0.75 Plan Apo with a doubler and loaded onto the local
drive for storage.
Statistical analyses
To deﬁne H-score cutoff values, we adopted the approach described by
Zlobec et al.37 for using the receiver operating characteristic (ROC). Using R
statistical environment version 2.3.3, we employed the pROC software
package to determine the sensitivity and speciﬁcity of H-score cutoff
values for each marker (Tables 2 and 3), with subsequent validation of the
most discriminatory cutoffs assessed using Kaplan–Meier curves derived
using the survival package within pROC (R Core Team: https://www.r-
project.org/38).
Descriptive characteristics and overall survival of patients were
evaluated according to histological subtype of lung tumor (adenocarci-
noma or squamous cell carcinoma). Cox proportional hazards analysis was
conducted exploring risk of death in lung adenocarcinoma or squamous
cell carcinoma patients, according to their expression levels of FLIP and
procaspase-8 in the tumoral nucleus or cytoplasm or the stromal nucleus
or cytoplasm. Analysis was conducted prior to and after adjustment for
potential confounders, such as age, sex, smoking status, tumor stage,
tumor grade, tumor size and extent of surgical resection conducted.
Follow-up was deﬁned as the date of surgery up to the date of death or
last known date of vital status. To explore the inﬂuence of early deaths in
the associations observed, sensitivity analysis was conducted after
removing lung cancer patients who died within the ﬁrst 6 months of
follow-up. Cox proportional hazards analysis was conducted in Stata
Version 11.2 (StataCorp, College Station, TX, USA). Based on a priori
biological plausibility, stratiﬁed analysis of risk of death in combined
Table 2. Risk of death in lung adenocarcinoma patients according to FLIP and procaspase-8 expression within the nucleus and cytoplasm in tumor
and stromal compartments
Alive, n= 35 (%) Dead, n= 51 (%) Unadjusted hazard ratios
(95% conﬁdence intervals)
Adjusteda hazard ratios
(95% conﬁdence intervals)
Tumoral FLIP nucleus
Low (p105) 24 (68.6) 27 (52.9) 1.00 1.00
High (4105) 11 (31.4) 24 (47.1) 1.62 (0.93–2.81) 1.50 (0.81–2.81)
Tumoral FLIP cytoplasm
Low (p172.5) 15 (42.9) 11 (21.6) 1.00 1.00
High (4172.5) 20 (57.1) 40 (78.4) 1.97 (1.01–3.84) 2.47 (1.14–5.35)
Stromal FLIP nucleus
Low (p74.5) 18 (51.4) 31 (60.8) 1.00 1.00
High (474.5) 17 (48.6) 20 (39.2) 0.79 (0.45–1.39) 0.75 (0.40–1.41)
Stromal FLIP cytoplasm
Low (p144.5) 17 (48.6) 33 (64.7) 1.00 1.00
High (4144.5) 18 (51.4) 18 (35.3) 0.65 (0.36–1.15) 0.57 (0.30–1.08)
Tumoral procaspase-8 nucleus
Low (p73.5) 6 (17.1) 16 (31.4) 1.00 1.00
High (473.5) 29 (82.9) 35 (68.6) 0.65 (0.36–1.18) 0.94 (0.40–2.19)
Tumoral procaspase-8 cytoplasm
Low (p155.5) 14 (40.0) 16 (31.4) 1.00 1.00
High (4155.5) 21 (60.0) 35 (68.6) 1.25 (0.69–2.27) 1.57 (0.75–3.31)
Stromal procaspase-8 nucleus
Low (p90.5) 15 (42.9) 39 (76.5) 1.00 1.00
High (490.5) 20 (57.1) 12 (23.5) 0.40 (0.21–0.76) 0.31 (0.15–0.66)
Stromal procaspase-8 cytoplasm
Low (p139.5) 22 (62.9) 42 (82.4) 1.00 1.00
High (4139.5) 13 (37.1) 9 (17.7) 0.51 (0.25–1.05) 0.51 (0.23–1.11)
aAdjustments included age, sex, smoking status, TNM stage, tumor size, tumor grade and surgery type.
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categories of high and low cytoplasmic FLIP and procaspase-8 expression
was evaluated.
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